Abbey Johnston1, Russell K Brynes, Kaveh Naemi, Niloufar Reisian, Deepty Bhansali, Xiaohui Zhao, Sherif A Rezk. 1. From the Departments of Pathology and Laboratory Medicine, University of California Irvine School of Medicine, Orange (Drs Johnston, Reisian, Bhansali, Zhao, and Rezk); the University of Southern California Keck School of Medicine, Los Angeles (Dr Brynes); and Pathology and Laboratory Medicine, University of California San Francisco Medical Center, San Francisco (Dr Naemi).
Abstract
CONTEXT: Lymphoid aggregates are seen in a minority of bone marrow biopsy specimens, and when present, their neoplastic nature is often apparent by morphologic evaluation. However, the distinction between benign and malignant aggregates can be a diagnostic challenge when there are multiple aggregates with no documented history of lymphoma. OBJECTIVE: To aid in the distinction between benign and malignant B-cell lymphoid aggregates. DESIGN: Previously, we described specific distribution patterns for B and T lymphocytes within bone marrow aggregates. To statistically analyze the significance of these patterns as well as previously reported criteria, we examined 128 bone marrow specimens with benign aggregates and 78 specimens with documented malignant B-cell aggregates and calculated specific odds ratios (ORs) and 95% confidence intervals (CIs) to aid in differentiating between benign and malignant B-cell aggregates. RESULTS: Aggregates with infiltrative edges (OR, 80.54; 95% CI, 31.76-204.21), a B-cell pattern (OR, 30.08; 95% CI, 13.28-68.10), paratrabecular location (OR, 10.17; 95% CI, 3.96-26.12), size greater than 600 μm (OR, 6.83: 95% CI, 3.61-12.93), or cytologic atypia correlated with malignancy. CONCLUSIONS: When taken collectively, the presence of more than 2 of these characteristic features was strongly predictive of malignancy.
CONTEXT: Lymphoid aggregates are seen in a minority of bone marrow biopsy specimens, and when present, their neoplastic nature is often apparent by morphologic evaluation. However, the distinction between benign and malignant aggregates can be a diagnostic challenge when there are multiple aggregates with no documented history of lymphoma. OBJECTIVE: To aid in the distinction between benign and malignant B-cell lymphoid aggregates. DESIGN: Previously, we described specific distribution patterns for B and T lymphocytes within bone marrow aggregates. To statistically analyze the significance of these patterns as well as previously reported criteria, we examined 128 bone marrow specimens with benign aggregates and 78 specimens with documented malignant B-cell aggregates and calculated specific odds ratios (ORs) and 95% confidence intervals (CIs) to aid in differentiating between benign and malignant B-cell aggregates. RESULTS: Aggregates with infiltrative edges (OR, 80.54; 95% CI, 31.76-204.21), a B-cell pattern (OR, 30.08; 95% CI, 13.28-68.10), paratrabecular location (OR, 10.17; 95% CI, 3.96-26.12), size greater than 600 μm (OR, 6.83: 95% CI, 3.61-12.93), or cytologic atypia correlated with malignancy. CONCLUSIONS: When taken collectively, the presence of more than 2 of these characteristic features was strongly predictive of malignancy.
Authors: Cyril Seillet; Elysa Carr; Derek Lacey; Michael D Stutz; Marc Pellegrini; Lachlan Whitehead; Joel Rimes; Edwin D Hawkins; Ben Roediger; Gabrielle T Belz; Philippe Bouillet Journal: Immunol Cell Biol Date: 2018-09-08 Impact factor: 5.126